Alcon’s Pazeo allergy drop available March 10

ATLANTA – Alcon’s new once daily Pazeo will be commercially available March 10, announced a company representative during a press conference here at SECO.Mike Burns, U.S. allergy brand manager for Alcon, said that Pazeo (olopatadine HCl ophthalmic solution 0.7%), which the FDA approved Jan. 30, will be available to doctors next week.

Fixed-dose combination therapy outperforms prostaglandin alone in reducing diurnal IOP

CORONADO, Calif. — Fixed-dose combination therapy significantly reduced diurnal IOP in patients with ocular hypertension or open-angle glaucoma, according to a poster presented at the American Glaucoma Society meeting.The multicenter randomized study included 88 patients who received brinzolamide 1%/brimonidine 0.2% fixed combination (BBFC) combined with a prostaglandin analogue and 94 patients who received vehicle combined with a prostaglandin analogue.

Custom sequence testing may accurately define glaucoma severity

CORONADO, Calif. — Custom sequence testing for relative afferent pupillary defect may objectively quantify disease severity compared with standard testing sequence, according to a presentation here.In a poster presented at the American Glaucoma Society meeting, Alice Williams, MD, and colleagues examined 49 patients with glaucoma who underwent relative afferent pupillary defect testing with the Konan RAPDx pupillograph using standard and custom testing sequences.